Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13322101 | 0.76 | DGAT1 (0.36) | KDM4EALDH1A1GAAAAK1 | |
| SCHEMBL2848178 | 0.76 | KDM4E (0.36) | KDM4EALDH1A1GAA | |
| SCHEMBL2844383 | 0.75 | KDM4E (0.34) | KDM4EITGA4ITGB7ALDH1A1GAA | |
| SCHEMBL17467122 | 0.75 | BACE1 (0.37) | KDM4EALDH1A1GAAAAK1 | |
| SCHEMBL3111363 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1GAA | |
| SCHEMBL3112360 | 0.74 | KDM4E (0.51) | KDM4EALDH1A1 | |
| SCHEMBL2847646 | 0.73 | KDM4E (0.34) | KDM4EALDH1A1GAA | |
| SCHEMBL2844180 | 0.72 | MTNR1A (0.34) | PDPK1KDM4EITGA4ITGB7ALDH1A1 | |
| SCHEMBL3128187 | 0.71 | KDM4E (0.35) | KDM4E | |
| SCHEMBL13303880 | 0.70 | KDM4E (0.35) | KDM4EALDH1A1GAAAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE3B, PDE2A | PDPK1 565/4885KDM4E 1383/4885ITGA4 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.